Dianthus Therapeutics 320% Year: What Investors Should Know as Stakes Shift
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
Get a concise action plan for financial emergencies, including prioritizing essentials, securing funds, and communicating with creditors promptly.
16,835 articlesDianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
When a hedge fund makes a substantive move in Genpact, it prompts investors to reassess the stock. This article break...
Rising APRs are transforming solar financing, exposing homeowners to longer paybacks and higher total costs. This rep...
DHL Supply Chain’s push to automation has rolled out 8,000 robots changing work across its global network, delivering...
Investors are looking a decade out at XRP, weighing regulatory clarity, RippleNet expansion, and new use cases as the...
A policy push to cover GLP-1 drugs for weight loss under Medicare stalled, leaving many beneficiaries in the middle. ...
Walmart CFO cites a drop in average gas fills as a sign of consumer stress, highlighting how higher fuel costs are sh...
Rivian is pursuing a Tesla-inspired playbook: start with a premium model, scale up production, then roll out a mass-m...
A potential policy showdown between a president and the Fed chair could ripple through markets. This piece explains t...
Trump’s Iran ceasefire plan draws fierce GOP skepticism, while financial markets react with oil and equities whipsaws...
Tune into Copart's Q3 2026 earnings transcript and discover what drives the CPRT stock, how margins are holding, and ...
When markets wobble, a single number can guide decisions. This article explains why beta matters and how a low-volati...